Adial Pharmaceuticals, Inc (ADIL) Financial Statements (2023 and earlier)
Company Profile
| Business Address |
1180 SEMINOLE TRAIL CHARLOTTESVILLE, VA 22901 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 5,753 | 9,157 | 12,689 | 6,062 | 7,180 | 5,210 | 5,638 | ||
| Cash and cash equivalents | 5,753 | 9,157 | 12,689 | 6,062 | 7,180 | 5,210 | 5,638 | ||
| Prepaid expense | 517 | 589 | 10 | 10 | 236 | 233 | 237 | ||
| Other undisclosed current assets | 504 | 194 | 266 | 390 | 570 | 147 | 298 | ||
| Total current assets: | 6,773 | 9,940 | 12,965 | 6,462 | 7,986 | 5,590 | 6,172 | ||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset | 259 | 271 | 283 | ||||||
| Operating lease, right-of-use asset | 207 | 221 | 234 | 246 | 259 | 271 | 283 | ||
| Property, plant and equipment | 52 | 54 | 56 | 58 | 62 | 62 | 30 | ||
| Intangible assets, net (including goodwill) | 254 | 254 | 254 | 254 | 137 | 137 | 137 | ||
| Goodwill | 249 | 249 | 249 | 249 | 131 | 131 | 131 | ||
| Intangible assets, net (excluding goodwill) | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||
| Other undisclosed noncurrent assets | 455 | 455 | 455 | 455 | 1,745 | 1,733 | 1,721 | ||
| Total noncurrent assets: | 968 | 984 | 999 | 1,013 | 2,461 | 2,473 | 2,453 | ||
| TOTAL ASSETS: | 7,742 | 10,923 | 13,964 | 7,475 | 10,446 | 8,063 | 8,625 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1,920 | 2,125 | 2,467 | 2,663 | 1,910 | 2,167 | 1,969 | ||
| Accounts payable | 278 | 618 | 415 | 286 | 185 | 477 | 637 | ||
| Accrued liabilities | 955 | 1,009 | 1,695 | 2,377 | 1,725 | 1,690 | 1,331 | ||
| Employee-related liabilities | 687 | 499 | 358 | ||||||
| Debt | 55 | 53 | 51 | 50 | 48 | 46 | 73 | ||
| Due to related parties | 30 | 175 | |||||||
| Other liabilities | 8 | 12 | 10 | 10 | |||||
| Other undisclosed current liabilities | (687) | (499) | (358) | ||||||
| Total current liabilities: | 1,327 | 1,867 | 2,171 | 2,722 | 1,958 | 2,213 | 2,042 | ||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 165 | 180 | 194 | 207 | 440 | 454 | 479 | ||
| Finance lease, liability | 220 | 227 | 240 | ||||||
| Operating lease, liability | 165 | 180 | 194 | 207 | 220 | 227 | 240 | ||
| Liabilities, other than long-term debt | 23 | 23 | 23 | 23 | |||||
| Deferred income tax liabilities | 23 | 23 | 23 | 23 | |||||
| Other undisclosed noncurrent liabilities | 817 | 892 | 868 | 1,014 | 628 | 339 | 247 | ||
| Total noncurrent liabilities: | 1,006 | 1,095 | 1,085 | 1,245 | 1,288 | 1,021 | 966 | ||
| Total liabilities: | 2,333 | 2,962 | 3,256 | 3,967 | 3,246 | 3,234 | 3,008 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 5,409 | 7,961 | 10,707 | 3,508 | 7,200 | 4,829 | 5,618 | ||
| Common stock | 27 | 26 | 24 | 21 | 20 | 18 | 17 | ||
| Additional paid in capital | 66,190 | 65,634 | 64,535 | 54,430 | 52,292 | 45,605 | 41,954 | ||
| Accumulated deficit | (60,808) | (57,698) | (53,851) | (50,943) | (45,112) | (40,794) | (36,354) | ||
| Total stockholders' equity: | 5,409 | 7,961 | 10,707 | 3,508 | 7,200 | 4,829 | 5,618 | ||
| TOTAL LIABILITIES AND EQUITY: | 7,742 | 10,923 | 13,964 | 7,475 | 10,446 | 8,063 | 8,625 | ||
Income Statement (P&L) ($ in thousands) Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (Other Income) | 5 | 17 | 29 | |||||
| Gross profit: | 5 | 17 | 29 | |||||
| Operating expenses | (3,188) | (3,830) | (3,059) | (5,981) | (4,064) | (4,404) | (4,840) | |
| Other undisclosed operating loss | (5) | (17) | (29) | |||||
| Operating loss: | (3,188) | (3,830) | (3,059) | (5,981) | (4,064) | (4,404) | (4,840) | |
| Nonoperating income (expense) | 78 | (17) | 151 | 56 | (254) | (37) | 7 | |
| Investment income, nonoperating | 78 | (17) | 146 | 56 | (272) | (66) | 7 | |
| Loss from continuing operations before income taxes: | (3,109) | (3,848) | (2,908) | (5,925) | (4,318) | (4,441) | (4,834) | |
| Other undisclosed income from continuing operations | 94 | |||||||
| Net loss available to common stockholders, diluted: | (3,109) | (3,848) | (2,908) | (5,831) | (4,318) | (4,441) | (4,834) | |
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2022 Q3 | 6/30/2022 Q2 | 3/31/2022 Q1 | 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (3,109) | (3,848) | (2,908) | (5,831) | (4,318) | (4,441) | (4,834) | |
| Comprehensive loss, net of tax, attributable to parent: | (3,109) | (3,848) | (2,908) | (5,831) | (4,318) | (4,441) | (4,834) | |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.